文献速递产科母胎医学

子痫前期的即时检验:诊断准确性研究的系统综述与荟萃分析

Point-of-Care Tests for Preeclampsia: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies.
PubMed 文献 · BJOG · 2024-12-11

该系统综述与荟萃分析检索了截至2024年5月的文献,纳入17项报告孕中晚期子痫前期短期预测即时检验诊断准确性的研究。仅糖基化纤连蛋白可行荟萃分析,合并敏感度0.80(95%CI 0.51-0.94),特异度0.84(95%CI 0.71-0.93),纳入5项研究且QUADAS评估均为低偏倚风险。作者认为即时糖基化纤连蛋白检测可能有助于高危人群的子痫前期临床分诊。

要点

  • 共纳入17项研究,涉及糖基化纤连蛋白、刚果红、胎盘生长因子(PlGF)等多种即时检验。
  • 仅糖基化纤连蛋白可行荟萃分析,合并敏感度0.80(95%CI 0.51-0.94),特异度0.84(95%CI 0.71-0.93)。
  • 作者认为即时糖基化纤连蛋白检测可能有助于高危人群的子痫前期临床分诊。

核心结论

  • 这些发现提示即时糖基化纤连蛋白检测可能有助于高危人群的子痫前期临床分诊。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed/Medline和Ovid Embase数据库自建库至2024年5月,纳入报告孕中晚期子痫前期短期预测即时检验诊断准确性的研究,共17项研究符合纳入标准。

主要发现

  • 17项研究中,6项描述糖基化纤连蛋白,5项描述刚果红,2项描述胎盘生长因子(PlGF),肾素、错误折叠蛋白、CD44/FKBPL比值和肌醇磷酸聚糖-P各1项研究。
  • 仅糖基化纤连蛋白可行荟萃分析,合并敏感度0.80(95%CI 0.51-0.94),特异度0.84(95%CI 0.71-0.93)。
  • 糖基化纤连蛋白荟萃分析纳入5项研究,QUADAS评估均为低偏倚风险。

关键数值与推荐

  • 糖基化纤连蛋白即时检验合并敏感度0.80(95%CI 0.51-0.94),合并特异度0.84(95%CI 0.71-0.93)。
  • 纳入研究的质量与偏倚风险采用QUADAS-2工具评估。

临床怎么用

  • 作者认为即时糖基化纤连蛋白检测可能有助于高危人群的子痫前期临床分诊。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preeclampsia is a common condition associated with significant maternal and foetal complications. The diagnosis of preeclampsia is based on clinical criteria, with recent introduction of angiogenic markers as an aid to clinical triage. Several biomarkers are now available in a point-of-care test format, which provide swift results to support clinical decision-making. OBJECTIVES: To determine sensitivity and specificity of available point-of-care tests used for preeclampsia prediction. SEARCH STRATEGY: Systematic searches of databases (PubMed/Medline, Ovid Embase) from inception till May 2024 were done to identify relevant studies. SELECTION CRITERIA: we included studies reporting on the diagnostic test accuracy of any point-of-care test for short-term prediction of preeclampsia in the second or third trimester. DATA COLLECTION AND ANALYSIS: Data were extracted using pre-designed template, and statistical analysis was performed to pool sensitivity and specificity and a hierarchal summary receiver operating characteristic curve model was used. Quality of included studies and risk of bias were assessed following the QUADAS-2 tool. MAIN RESULTS: We identified 17 studies that met the inclusion criteria, six of which described the use of glycosylated fibronectin, five with Congo red, two with placental growth factor (PlGF) and one study each investigated nephrin, misfolded protein, CD44/FKBPL ratio and inositol phosphoglycan-P. Meta-analysis was possible only for glycosylated fibronectin with a pooled sensitivity of 0.80 (95% CI: 0.51-0.94) and a specificity of 0.84 (95% CI: 0.71-0.93). Five studies were included in meta-analysis, all of which had a low risk of bias on the QUADAS assessment. CONCLUSIONS: These findings suggest that the point-of-care glycosylated fibronectin testing might be beneficial in clinical triage for preeclampsia in an at-risk population.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Elbarbary N, Pritsini F, Kazi A, et al. Point-of-Care Tests for Preeclampsia: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies. BJOG. 2024. PMID: 39663778. doi:10.1111/1471-0528.18040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。